Filtered By:
Vaccination: Meningitis Vaccine
This page shows you your search results in order of date. This is page number 5.
Order by Relevance | Date
Total 2891 results found since Jan 2013.
The serotype-specific prevalence of pneumococci in hospitalized pneumonia patients with COPD: a prospective, multi-center, cohort study
CONCLUSIONS: Serotypes 22F, 6A, and 6B, which are covered either by PPV 23 or by PCV 13, are still common pneumococcal serotypes in COPD pneumonia in the post-vaccination era in Korea.PMID:37586811 | DOI:10.3904/kjim.2023.152
Source: The Korean Journal of Internal Medicine - August 16, 2023 Category: Internal Medicine Authors: Jae Yeol Kim Jae-Woo Jung Min-Jong Kang Deog Kyeom Kim Hayoung Choi Young-Jae Cho Seung Hun Jang Chang-Hoon Lee Yeon Mok Oh Ji Sook Park Source Type: research
The Impact of Routine Vaccinations on Alzheimer's Disease Risk in Persons 65 Years and Older: A Claims-Based Cohort Study using Propensity Score Matching
CONCLUSION: Several vaccinations, including Tdap/Td, HZ, and pneumococcal, are associated with a reduced risk for developing AD.PMID:37574727 | DOI:10.3233/JAD-221231
Source: Herpes - August 14, 2023 Category: Infectious Diseases Authors: Kristofer Harris Yaobin Ling Avram S Bukhbinder Luyao Chen Kamal N Phelps Gabriela Cruz Jenna Thomas Yejin Kim Xiaoqian Jiang Paul E Schulz Source Type: research
Stability of lyophilized Meningococcal A conjugate vaccine, (MenAfriVac ™) at elevated temperatures to support controlled temperature chain (CTC) claim
Biologicals. 2023 Aug 8;83:101698. doi: 10.1016/j.biologicals.2023.101698. Online ahead of print.ABSTRACTMeningococcal A Conjugate Vaccine (MenAfriVac) is the world's first Monovalent Conjugate Vaccine against Neisseria Meningitidis serogroup A which has obtained Controlled Temperature Chain (CTC) label claim of "stable upto 40°C for 4 days prior to reconstitution" developed by Serum Institute of India Pvt. Ltd. Pune, India and the vaccine was granted permission from World health Organization. This paper elucidates and talks about the layout of various studies performed to characterize the product to declare as CTC at the...
Source: Biologicals : Journal of the International Association of Biological Standardization - August 10, 2023 Category: Biotechnology Authors: Sunil Gairola Prashant Bonde Pankaj Sharma Sameer Kale Sunil Goel Suresh Jadhav Source Type: research
Distribution of serotypes causing invasive pneumococcal disease in older adults from high-income countries and impact of pediatric and adult vaccination policies
CONCLUSIONS: Vaccinating older adults with higher-valency PCVs, especially PCV20, could substantially reduce the remaining IPD burden in high-income countries, regardless of current PCV use in pediatric NIPs and adult PPSV23 policies.PMID:37544825 | DOI:10.1016/j.vaccine.2023.08.001
Source: Vaccine - August 6, 2023 Category: Allergy & Immunology Authors: Lindsay R Grant Mary P E Slack Christian Theilacker Jelena Vojicic St éphane Dion Ralf-Rene Reinert Luis Jodar Bradford D Gessner Source Type: research
Impact of methotrexate treatment on vaccines immunogenicity in adult rheumatological patients - Lessons learned from the COVID-19 pandemic
Biomed Pharmacother. 2023 Aug 3;165:115254. doi: 10.1016/j.biopha.2023.115254. Online ahead of print.ABSTRACTDespite the development of new biological and synthetic targeted therapies, methotrexate remains one of the most commonly used immunomodulatory drugs in rheumatology. However, its effect on the immunogenicity of vaccines has been studied only to a limited extent until recently, resulting in the lack of clear guidelines on the use of methotrexate during vaccination. Significant progress was made during the COVID-19 pandemic due to the dynamic development of research on vaccines, including patients with autoimmune inf...
Source: Herpes - August 5, 2023 Category: Infectious Diseases Authors: Jakub Wro ński Marzena Ciechomska Ewa Kuca-Warnawin Source Type: research
Variability of in vivo potency assays of whole-cell pertussis, inactivated polio, and meningococcal B vaccines
Vaccine. 2023 Jul 30:S0264-410X(23)00885-X. doi: 10.1016/j.vaccine.2023.07.054. Online ahead of print.ABSTRACTFor the batch release of vaccines, potency release assays are required. Non-animal in vitro tests have numerous advantages and are preferred; however, several vaccines are still released using in vivo assays. Their major drawback is the inherent variability with its practical implications. We quantified the variability of in vivo potency release assays for whole-cell pertussis, inactivated polio and meningococcal B (MenB) vaccines which showed large CV (Coefficient of Variation) ranging from 34% to 125%. As inheren...
Source: Vaccine - August 1, 2023 Category: Allergy & Immunology Authors: Cerissa van Walstijn Stefan Verweij Rory Care Peter Rigsby Eli-Boaz Clapper Kevin Markey Rob J Vandebriel Paul Stickings Marcel H N Hoefnagel Source Type: research
Effectiveness of thirteen-valent pneumococcal conjugate vaccine to prevent serotype 3 invasive pneumococcal disease in Quebec in children, Canada
The objective was to estimate PCV13 effectiveness to prevent serotype 3 invasive pneumococcal disease in children aged less than 5 years, using 2010-2018 mandatory notification and laboratory surveillance data, an indirect cohort design and multivariate logistic regression models. A total of 29 cases of serotype 3 and 290 non-vaccine serotype cases as controls were analysed. Overall vaccine effectiveness (≥1 dose) was estimated at 59% [-39% to 88%]. During the first year after the last dose effectivness was 88% [47% to 97%] whereas no protection was observed thereafter. There was no trend towards increased effectiveness ...
Source: Vaccine - July 31, 2023 Category: Allergy & Immunology Authors: Genevi ève Deceuninck Nicholas Brousseau Brigitte Lefebvre Caroline Quach Bruce Tapiero Yen-Giang Bui Micha ël Desjardins Philippe De Wals Source Type: research
